Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a shorter drug course beat a longer one for a deadly fungal infection?

NCT ID NCT07743593

Disease control Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Sep 04, 2026 · Updated 3 times

Summary

This trial is testing whether a 10-week course of fluconazole works as well as the standard 24-week course for people with HIV who have a cryptococcal infection in their blood (antigenemia) but no symptoms. It also compares starting HIV medications right away versus waiting 14 days. The goal is to see which approach helps people survive without developing meningitis or needing hospitalization. The study involves 505 adults in Uganda and follows them for 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fluconazole and antiretroviral therapy (ART)
What this could lead to
If successful, this could lead to shorter, simpler treatment regimens for cryptococcal antigenemia, reducing side effects and improving outcomes for people with HIV.
What could go wrong
The trial is still in progress, and results may not confirm that the shorter regimen is as effective. There are risks of side effects from fluconazole and potential complications from ART timing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 505 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * HIV-1 infection * Age greater than 18 years * Ability and willingness to give informed consent * Plasma or serum cryptococcal antigen positive with titer less than 1:160 Exclusion Criteria: * Cannot or unlikely to attend regular clinic visits * History of cryptococcal infection * Symptomatic meningitis confirmed by cerebrospinal fluid cryptococcal antigen positivity * More than 10 weeks of fluconazole therapy * Pregnancy confirmed by urinary or serum pregnancy test * Current breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cryptococcal antigenemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cryptococcosis HIV infectious disease Cryptococcal meningitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cryptococcal antigenemia Cryptococcal infection Cryptococcal meningitis HIV-1-infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Infectious Diseases Institute, Makerere University

    Kampala, Uganda

More trials for these conditions

Other studies related to the condition(s) this trial covers.